Mineralys Therapeutics (MLYS) CEO Congleton Sells $2M of Stock
Jon Congleton sold 75,000 shares for $1,960,462 on June 30, 2026.
Reviewed by automated data checks against the source filing. How we make and check alerts
Jon Congleton, Chief Executive Officer at Mineralys Therapeutics, Inc. ($MLYS), sold 75,000 shares at an average price of $26.14, worth about $1.96 million, on June 30, 2026. The trade was reported to the SEC in a Form 4 filing and was made under a pre-arranged Rule 10b5-1 trading plan.
Since the trade, $MLYS is up 12.9% after 1 week, down 2.9% after 1 month and down 24.8% to date (from the $26.98 close on Jun 30, 2026).
MLYS
Mineralys Therapeutics, Inc.
Key Points
- Jon Congleton, the CEO of Mineralys Therapeutics, sold 75,000 shares valued at approximately $1.96 million on June 30, 2026.
- Mineralys Therapeutics has a market cap of about $2.5 billion and trades at $26.98, down from a 52-week high of $47.65.
- Analysts have a consensus price target of $48.5 for Mineralys Therapeutics, with ratings ranging from Buy to Neutral.
Get $MLYS trade alerts by text
We text you when insiders, Congress or big funds trade $MLYS. Free.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Mineralys Therapeutics, Inc. alert may contain errors. Disclosures
CEO Jon Congleton's Share Sale
Jon Congleton, Chief Executive Officer of Mineralys Therapeutics, Inc. (NasdaqGS: MLYS), sold 75,000 shares on June 30, 2026. The sale was valued at about $1,960,462 based on a price of $26.14 per share. This transaction was part of a planned selling strategy.
Context of the Sale
Congleton's sale represents a reduction in his stake in the company, which continues to develop treatments targeting diseases linked to aldosterone. The CEO's decision to sell could be seen as part of personal financial planning rather than a reflection of the company's performance.
Recent Activity by Other Insiders
Earlier, Eric Warren, Chief Commercial Officer, purchased 104,124 shares on June 26, 2026, totaling about $1,378,602. Meanwhile, Rodman David Malcom, the Chief Medical Officer, also engaged in recent insider trading, buying 4,584 shares on June 17 and selling the same amount later that day. This flurry of insider activity highlights a period of significant trading among the company's executives.
How Mineralys Therapeutics, Inc. Stock Has Traded
As of June 30, 2026, Mineralys Therapeutics shares traded at $26.98. This price is considerably lower than its 52-week high of $47.65, suggesting the stock has faced challenges. Investors may find it essential to monitor how this insider selling affects market sentiment in the coming weeks.
Analysts Set New Price Targets
On October 12, 2026, UBS initiated coverage on Mineralys Therapeutics with a Neutral rating and a price target of $29.0. Meanwhile, HC Wainwright & Co. reiterated a Buy rating with a target of $56.0 on the same date. The consensus among analysts gives a mean price target of $48.5, indicating some optimism about the company's future despite its current stock price.
What Mineralys Therapeutics, Inc. Does
Mineralys Therapeutics, based in Radnor, Pennsylvania, develops innovative treatments for conditions related to aldosterone dysregulation. With a focus on cardiorenal conditions, the company's pipeline includes a promising aldosterone synthase inhibitor currently under development.
Next Steps
Investors should keep an eye on the upcoming earnings release scheduled for November 10, 2026. This will provide a clearer picture of the company's financial health and any potential shifts following recent insider transactions. Remember, the Form 4 filing reflects trades that occurred in the past and may not represent current holdings.
Related Filing Alerts
Source: Jon Congleton's Form 4 filing on $MLYS (Jun 30, 2026). Find the original filing: MLYS Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts